{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+to+Skin&page=36",
    "query": {
      "condition": "Skin to Skin",
      "page": 36
    },
    "page_size": 10
  },
  "pagination": {
    "page": 36,
    "page_size": 10,
    "total_count": 6448,
    "total_pages": 645,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+to+Skin&page=37&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+to+Skin&page=35&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T16:02:45.526Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02837575",
      "title": "Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Herpes Genitalis"
      ],
      "interventions": [
        {
          "name": "VCL-HB01",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Phosphate-buffered saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Vical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 261,
      "start_date": "2016-09",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2019-02-27",
      "last_synced_at": "2026-10-30T16:02:45.526Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • San Diego, California • Hollywood, Florida + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02837575"
    },
    {
      "nct_id": "NCT03406962",
      "title": "MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Inherited Metabolic Disorders (IMD)"
      ],
      "interventions": [
        {
          "name": "MGTA-456",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Magenta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "0 Years to 17 Years"
      },
      "enrollment_count": 8,
      "start_date": "2018-02-09",
      "completion_date": "2021-01-15",
      "has_results": true,
      "last_update_posted_date": "2021-11-03",
      "last_synced_at": "2026-10-30T16:02:45.526Z",
      "location_count": 2,
      "location_summary": "Minneapolis, Minnesota • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03406962"
    },
    {
      "nct_id": "NCT01494922",
      "title": "Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Reduction in Severity of Skin Scarring"
      ],
      "interventions": [
        {
          "name": "EXC 001 (currently called PF-06473871)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 14,
      "start_date": "2011-12-08",
      "completion_date": "2013-09-10",
      "has_results": true,
      "last_update_posted_date": "2021-08-13",
      "last_synced_at": "2026-10-30T16:02:45.526Z",
      "location_count": 4,
      "location_summary": "Lake Worth, Florida • Chicago, Illinois • Eugene, Oregon + 1 more",
      "locations": [
        {
          "city": "Lake Worth",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Eugene",
          "state": "Oregon"
        },
        {
          "city": "Tualatin",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01494922"
    },
    {
      "nct_id": "NCT01876329",
      "title": "Autoantibodies to Gastric Parietal Cells in Rheumatoid Arthritis Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Vitamin B12 Deficiency"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Keesler Air Force Base Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2013-06",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2015-05-29",
      "last_synced_at": "2026-10-30T16:02:45.526Z",
      "location_count": 1,
      "location_summary": "Keesler Air Force Base, Mississippi",
      "locations": [
        {
          "city": "Keesler Air Force Base",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01876329"
    },
    {
      "nct_id": "NCT05727839",
      "title": "Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cutaneous Tumor",
        "Malignant Solid Tumor"
      ],
      "interventions": [
        {
          "name": "JCXH-211 Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Immorna Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 19,
      "start_date": "2023-02-24",
      "completion_date": "2024-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-10-30T16:02:45.526Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05727839"
    },
    {
      "nct_id": "NCT02910557",
      "title": "Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Melanoma",
        "Herpetic Infection"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 187,
      "start_date": "2017-08-10",
      "completion_date": "2026-01-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-10-30T16:02:45.526Z",
      "location_count": 9,
      "location_summary": "Coral Springs, Florida • Baltimore, Maryland • Jefferson City, Missouri + 5 more",
      "locations": [
        {
          "city": "Coral Springs",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Jefferson City",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02910557"
    },
    {
      "nct_id": "NCT01859845",
      "title": "Melanoma Simulation Model With Smartphone Devices: Training Physicians for Early Detection of Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Smartphone",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2013-04",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2014-08-01",
      "last_synced_at": "2026-10-30T16:02:45.526Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01859845"
    },
    {
      "nct_id": "NCT00430495",
      "title": "A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Atacicept",
          "type": "DRUG"
        },
        {
          "name": "Placebo matched to atacicept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 256,
      "start_date": "2006-12",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2016-02-17",
      "last_synced_at": "2026-10-30T16:02:45.526Z",
      "location_count": 1,
      "location_summary": "Rockland, Massachusetts",
      "locations": [
        {
          "city": "Rockland",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00430495"
    },
    {
      "nct_id": "NCT03633877",
      "title": "Durapore vs. Hy-Tape to Secure The Endotracheal Tube",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Erythema"
      ],
      "interventions": [
        {
          "name": "DuraporeTM and Hy-Tape®",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Tufts Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 112,
      "start_date": "2018-09-17",
      "completion_date": "2019-10-11",
      "has_results": false,
      "last_update_posted_date": "2021-09-14",
      "last_synced_at": "2026-10-30T16:02:45.526Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03633877"
    },
    {
      "nct_id": "NCT05113251",
      "title": "Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Breast Cancer",
        "HER2-positive Early Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Trastuzumab Deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 927,
      "start_date": "2021-10-25",
      "completion_date": "2027-04-30",
      "has_results": true,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-10-30T16:02:45.526Z",
      "location_count": 22,
      "location_summary": "Springdale, Arkansas • Beverly Hills, California • Glendale, California + 19 more",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05113251"
    }
  ]
}